Novartis (NVS) is close to a deal to purchase Avidity Biosciences (RNA) for more than $70 per share, Michelle Davis of Bloomberg reports, citing a person familiar with the matter. The deal could be announced as early as Sunday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- NVS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Citizens JMP healthcare analysts hold an analyst/industry conference call
- Trump Trade: Trump administration prepares new probe into pharma prices
- Novartis announces expiration of HSR Act waiting period of Tourmaline Bio offer
- Novartis announces Cosentyx met primary endpoint in Phase III REPLENISH trial